- Home
- IMCR vs EWTX Comparison
IMCR vs EWTX Comparison
Compare IMCR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- EWTX
- Stock Information
- Founded
- IMCR 2008
- EWTX 2017
- Country
- IMCR United Kingdom
- EWTX United States
- Employees
- IMCR N/A
- EWTX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- EWTX Health Care
- Exchange
- IMCR Nasdaq
- EWTX Nasdaq
- Market Cap
- IMCR 1.7B
- EWTX 1.6B
- IPO Year
- IMCR 2021
- EWTX 2021
- Fundamental
- Price
- IMCR $33.50
- EWTX $15.96
- Analyst Decision
- IMCR Buy
- EWTX Buy
- Analyst Count
- IMCR 9
- EWTX 10
- Target Price
- IMCR $62.38
- EWTX $37.90
- AVG Volume (30 Days)
- IMCR 350.0K
- EWTX 762.7K
- Earning Date
- IMCR 11-06-2025
- EWTX 11-06-2025
- Dividend Yield
- IMCR N/A
- EWTX N/A
- EPS Growth
- IMCR N/A
- EWTX N/A
- EPS
- IMCR N/A
- EWTX N/A
- Revenue
- IMCR $356,145,000.00
- EWTX N/A
- Revenue This Year
- IMCR $29.99
- EWTX N/A
- Revenue Next Year
- IMCR $8.85
- EWTX N/A
- P/E Ratio
- IMCR N/A
- EWTX N/A
- Revenue Growth
- IMCR 26.78
- EWTX N/A
- 52 Week Low
- IMCR $23.15
- EWTX $10.60
- 52 Week High
- IMCR $39.33
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- IMCR 49.73
- EWTX 55.61
- Support Level
- IMCR $31.36
- EWTX $14.68
- Resistance Level
- IMCR $34.18
- EWTX $16.37
- Average True Range (ATR)
- IMCR 1.38
- EWTX 0.81
- MACD
- IMCR -0.00
- EWTX 0.03
- Stochastic Oscillator
- IMCR 60.51
- EWTX 75.44
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.